STOK · Stoke Therapeutics, Inc.
$23.95
-0.34 (-1.40%)
At close · Oct 8
Return incl. dividend (before tax)
Market Cap
$1.57B
Shares
64.53M
Volume · Oct 8
55.65K
Avg daily vol (3M)
854.52K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$24.29
Open$24.13
Day$23.95–24.70
52W close$22.37–38.35
Avg vol 30d928K
Short int11.2M · 17.3% float · 17.3d
Short vol72%
Last earningsAug 3, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 3
Up next
Next earnings call
Oct 28, 2026
Est · unconfirmed
· in 3 wks
filed Aug 3, 2026
call held Aug 3, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$27.59M
Trailing 12 months
Net income (TTM)
−$207.90M
Trailing 12 months
Revenue growth YoY
-32.5%
Year over year
Operating margin
-809.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-11.3%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$110.00M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+13.1%
Year over year · more shares
Price change (1Y)
-9.1%
Trailing year
Short interest
17.3%
Latest settlement · 17.3 days to cover
AI Brief
Q2 FY26 earnings call · Aug 3, 2026
Q2 FY26
TL;DR. Stoke completed enrollment of 162 patients in its Phase 3 EMPEROR study of zorevunersen in Dravet syndrome with a Q3 2027 data readout planned, and is preparing for a pre-NDA meeting with the FDA in H2 2026 ahead of an initiating rolling NDA submission in Q1 2027. The company also reported a Q2 net loss of $61.6M and ended with $420M in pro forma cash, expected to fund operations through a potential early-2028 launch.
Bullish
- + Phase 3 EMPEROR enrollment of 162 patients completed with no discontinuations and a Q3 2027 data readout planned
- + Rolling NDA submission planned to initiate in Q1 2027 following a pre-NDA meeting with FDA in H2 2026
- + Pro forma cash of $420M expected to fund operations through potential U.S. launch by early 2028
- + Phase 1 OSPREY study of STK-002 in ADOA advanced with sentinel cohort dosed and initial data anticipated in H1 2027
Bearish
- − Q2 net loss widened to $61.6M (vs $23.5M prior year quarter) driven by higher R&D and SG&A
- − Q2 revenue declined to $9.3M from $13.8M in the prior year quarter
- − YTD revenue fell sharply to $15.6M from $172.4M due to non-recurrence of a prior Biogen IP license performance obligation
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.63
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−23%
below
Price vs 50-day avg
−18%
below
RSI (14)
30
oversold
MACD trend
Negative
52-week position
12%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−19%
trailing
6-month return
−31%
trailing
YTD return
−23%
this year
Relative strength
−42%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $30 › 200d $32 — 200d above 50d
Institutional flow
Distributing
1 of 198 funds reported for Sep 30 · net -178 sh shares
Insider flow
Distributing
Net -$646.9K over 90 days · 100% sells
Short interest
Falling
17.28% of float · ▼ -0.5% MoM · 17.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
198 holders — near 3-yr high, broad support
Squeeze score
62
elevated · 0–100
Fundamentals
Revenue growth
+405%
Y/Y
EPS growth
+93%
Y/Y
Free cash flow
$44.9M
Quant / Vol
risk profile
Volatility
59%
annualized · 1-yr
Max drawdown
−37%
past year
ATR
5.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−23%
Bearish
Price vs 50-day avg
−18%
Bearish
RSI (14)
30
Neutral
MACD trend
Negative
Bearish
52-week position
12%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $30 › 200d $32 — 200d above 50d
Institutional flow
Distributing
1 of 198 funds reported for Sep 30 · net -178 sh shares
Insider flow
Distributing
Net -$646.9K over 90 days · 100% sells
Short interest
Falling
17.28% of float · ▼ -0.5% MoM · 17.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
198 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $22
Now $24 · 12%
Range high $38
vs 200-day avg -23%
vs 50-day avg -18%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
STOK
this stock
Stoke Therapeutics, Inc.
|
$1.57B | -23.5% | +404.5% | — | 17.3% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.16B | +11.5% | +46.2% | 29.5 | 1.9% |
|
MRNA
Moderna, Inc.
|
$78.44B | +566.3% | +4.3% | — | 8.2% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.40B | -3.9% | +20.8% | 18.4 | 2.5% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| STOK | -6.6% | -18.8% | -31.3% | -6.6% | -23.5% |
| SPY | +1.9% | +1.9% | +10.8% | +1.9% | +14.0% |
| vs SPY | -8.5% | -20.8% | -42.0% | -8.5% | -37.5% |